DexCom Inc $ 367.50 3.38 (0.93%)
Volume:
688,961
Avg Vol (1m):
1,065,546
Market Cap $:
35.29 Bil
Enterprise Value $:
34.50 Bil
P/E (TTM):
151.84
P/B:
23.53
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 1.43 | ||
| Equity-to-Asset | 0.39 | ||
| Debt-to-Equity | 1.21 | ||
| Debt-to-EBITDA | 4.86 | ||
| Interest Coverage | 3.94 | ||
| Piotroski F-Score | 6 | ||
| Altman Z-Score | 10.39 | ||
| Beneish M-Score | -2.36 | ||
| WACC vs ROIC | |||
Profitability Rank | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | 16.31 | ||
| Net Margin % | 12.69 | ||
| ROE % | 21.26 | ||
| ROA % | 8.03 | ||
| ROC (Joel Greenblatt) % | 56.64 | ||
| 3-Year Revenue Growth Rate | 32.6 |
DXCM
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PE Ratio | 151.84 | ||
| Forward PE Ratio | 118.74 | ||
| PE Ratio without NRI | 151.84 | ||
| Price-to-Owner-Earnings | 202.16 | ||
| PB Ratio | 23.53 | ||
| PS Ratio | 19.33 | ||
| Price-to-Free-Cash-Flow | 134.19 | ||
| Price-to-Operating-Cash-Flow | 79.12 | ||
| EV-to-EBIT | 110.09 | ||
| EV-to-EBITDA | 92.16 | ||
| EV-to-Revenue | 18.93 | ||
| Current Ratio | 6.39 | ||
| Quick Ratio | 6 | ||
| Days Inventory | 86.64 | ||
| Days Sales Outstanding | 74.18 | ||
| Days Payable | 85.47 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -2.7 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 23.83 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 16.67 | ||
| Price-to-Median-PS-Value | 1.42 | ||
| Price-to-Graham-Number | 12.68 | ||
| Earnings Yield (Greenblatt) % | 0.92 |